SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

EVOLVE II Diabetes Substudy

EVOLVE II Diabetes Substudy is a consecutive, multicentre,
single-arm, non-randomized study, with the SYNERGY stent
in medically-treated diabetic patients.

  • Patients with ≤3 native coronary artery lesions in ≤2 major
    epicardial vessels;
  • Lesion length ≤34 mm, RVD ≥2.25 mm ≤ 4.0, % DS≥50<100
SYNERGY Stent Investigator Sponsored Research Infographic
* Patients who did not receive a study stent were only followed through 1 year (safety population) Presented by M Gilard, PCR 2017. cc

SYNERGY Yields Exceptional Comparable Clinical Outcomes for Diabetic Patients and EVOLVE II RCT

SYNERGY™ BP Stent shows comparable clinical outcomes in patients with DM and EVOLVE II RCT that included a broad range of patient

  • The 4-year data provides evidence supporting safety and efficacy of the SYNERGY stent in patients with diabetes mellitus
  • Low clinical event rates were maintained through 4-years, with TLF 12.2% and all-cause death 4.4%

Outstanding Safety

0% Def/Prob ST after 30 days in diabetic patients treated with SYNERGY™ BP Stent, suggesting optimal early healing in this complex patient population.
SYNERGY Stent Investigator Sponsored Research Infographic
Presented by M Gilard, PCR 2017. cc
Top